UNSPSC 51161541: Fluprofylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C22H26FN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Y42K4JRBJ, chemically known as 1h-purine-2,6-dione, 7-(3-(4-(4-fluorobenzoyl)-1-piperidinyl)propyl)-3,7-dihydro-1,3-dimethyl- but generally known as fluprofylline, which bears US NIH Compound Identifier 65636. European Medicines Agency schedules Fluprofylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07738MIG.

UNSPSC 51161541 Fluprofylline, a Commodity code, covers pharmaceutical manufacturing and supply contracts that state and local government purchasing entities are actively soliciting for multi-source generic pharmaceuticals and over-the-counter products. Recent activity shows state and local procurement offices and their cooperative purchasing alliances are seeking manufacturers capable of supplying identified pharmaceutical products with specific National Drug Codes (NDCs) to authorized drug wholesalers serving government facilities, hospitals, clinics, and related healthcare operations across multiple jurisdictions. Vendors must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), and hold contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with chargeback systems in place. Manufacturers must offer flexible pricing structures—flat price, net price formats (NF30, NF60, NF90), or WAC-minus—and carry comprehensive insurance coverage including workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Products must comply with FDA requirements, possess expiration dates of at least one year from manufacture, and maintain a minimum six-month shelf life.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, with a proposal due date of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating state and local government facilities. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing (10 percent), compliance with administrative fee data format and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Contract terms span two years for new responders with optional MMCAP extensions, while incumbent vendor amendments align with existing expiration dates through June 30, 2028. Vendors must submit proposals through the ePro procurement system with pricing and product information in designated Excel spreadsheet format converted to CSV, and the question cutoff date is February 18, 2026.